{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.14","value":"133.94"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) were administered with 2.5 milligram per kilogram (mg/kg) belantamab mafodotin intravenous (IV) infusion over 30-60 minutes on day 1 of each 21-days cycle. Participants were treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.","id":"OG000","title":"Belantamab Mafodotin"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) population. Only those participants with data available at specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 168 hours","title":"Area Under the Concentration-time Curve From Time 0 to 168h (AUC[0-168]) of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}